Holen Sie sich die Stockscreener-App
0.9403
7.81%
-0.0797
Vorhandelsmarkt:
.95
0.0097
+1.03%
Schlusskurs vom Vortag:
$1.02
Offen:
$1
24-Stunden-Volumen:
384.93K
Relative Volume:
0.83
Marktkapitalisierung:
$63.70M
Einnahmen:
$208.60K
Nettoeinkommen (Verlust:
$-58.59M
KGV:
-1.0261
EPS:
-0.9164
Netto-Cashflow:
$-47.11M
1W Leistung:
+6.85%
1M Leistung:
+0.72%
6M Leistung:
-27.11%
1J Leistung:
-29.30%
1-Tages-Spanne:
$0.9401
$1.07
1-Wochen-Bereich:
$0.81
$1.07
52-Wochen-Spanne:
$0.7113
$1.94
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
0.9403 | 69.10M | 208.60K | -58.59M | -47.11M | -0.9164 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-09-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-02-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-04-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-05 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-06-05 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-01-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-10 | Eingeleitet | Credit Suisse | Outperform |
| 2018-07-13 | Eingeleitet | BMO Capital Markets | Outperform |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-28 | Eingeleitet | SunTrust | Buy |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Inflarx N V Aktie (IFRX) Neueste Nachrichten
Treasury Yields: Can InflaRx NV sustain earnings growth2026 Earnings Surprises & Daily Stock Momentum Reports - baoquankhu1.vn
Can InflaRx's Vilobelimab Stage A Revival In Pyoderma Gangrenosum? - RTTNews
HC Wainwright Forecasts InflaRx's Q3 Earnings (NASDAQ:IFRX) - MarketBeat
Analyst Upgrade: Is InflaRx NV a top pick in the sector2026 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Aug Shorts: Can InflaRx NV sustain earnings growthMarket Movement Recap & Community Trade Idea Sharing - baoquankhu1.vn
Bear Alert: Is InflaRx NV a top pick in the sector2026 Gainers & Daily Momentum Trading Reports - baoquankhu1.vn
InflaRx NV (IFRX) reports Q4 loss, lags revenue estimates - MSN
Raymond James raises Inflarx stock price target on drug trial data - Investing.com India
InflaRx Survival Hopes Rest On Izicopan - Citeline News & Insights
InflaRx (NASDAQ:IFRX) Given New $14.00 Price Target at Guggenheim - MarketBeat
Guggenheim cuts Inflarx stock price target on model update to $14 - Investing.com Canada
Guggenheim cuts Inflarx stock price target on model update to $14 By Investing.com - Investing.com Australia
Q1 Earnings Forecast for InflaRx Issued By HC Wainwright - MarketBeat
InflaRx (IFRX) posts 2025 loss, relies on cash runway and grants - Stock Titan
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
InflaRx NV reports results for the quarter ended December 31Earnings Summary - TradingView
IFRX: Izicopan's promising Phase 2a data drives strategic focus and extends cash runway to mid-2027 - TradingView
InflaRx (NASDAQ:IFRX) Issues Earnings Results, Meets Expectations - MarketBeat
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027 - TipRanks
Inflarx reports full year 2025 results and highlights key achievements and expected milestones - marketscreener.com
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones - The Manila Times
InflaRx (IFRX) narrows 2025 loss, shifts focus to izicopan growth - Stock Titan
IFRX: Izicopan advances as the lead asset with strong Phase 2a data, cost cuts, and extended cash runway - TradingView
InflaRx N.V. (IFRX) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
InflaRx to present Phase 3 pyoderma gangrenosum data at AAD By Investing.com - Investing.com South Africa
InflaRx FY 2025 earnings preview - MSN
Aug Opening: Is InflaRx NV forming bullish engulfing patterns2026 PreEarnings & Precise Buy Zone Tips - baoquankhu1.vn
Aug Levels: Can InflaRx NV outperform under higher oil prices2026 Growth vs Value & Verified Swing Trading Watchlist - baoquankhu1.vn
InflaRx (IFRX) director Mark Kubler reports 960,015 shares and multiple options - Stock Titan
InflaRx (IFRX) director lists options and 10,000 Ordinary Shares - Stock Titan
InflaRx (IFRX) director Brudnick reports shares and multiple stock option grants - Stock Titan
InflaRx (IFRX) director details vested and future stock options - Stock Titan
InflaRx (IFRX) CSO discloses 1.76M shares and multiple option grants - Stock Titan
InflaRx (IFRX) officer discloses vested and performance stock options - Stock Titan
InflaRx (IFRX) director discloses sizeable share and option stakes - Stock Titan
InflaRx (IFRX) CEO reports 1,068,908 shares plus option grants - Stock Titan
InflaRx (IFRX) CFO details extensive stock option and share holdings - Stock Titan
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting - The Manila Times
InflaRx N.V. to Present Phase 3 Study Data on Vilobelimab for Pyoderma Gangrenosum at AAD 2026 Annual Meeting - Quiver Quantitative
Vilobelimab Phase 3 data earns late-breaker slot at AAD 2026 meeting - Stock Titan
InflaRx NV expected to post a loss of 15 cents a shareEarnings Preview - TradingView
InflaRx (IFRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
InflaRx receives Nasdaq notification - MSN
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Sahm
InflaRx receives Nasdaq notice over minimum bid price rule By Investing.com - Investing.com South Africa
InflaRx Receives Nasdaq Deficiency Notice Over Minimum Bid Price - National Today
InflaRx (IFRX) hit with Nasdaq minimum $1 bid-price warning and cure window - Stock Titan
InflaRx receives Nasdaq notice over minimum bid price rule - Investing.com
InflaRx to Report Full Year 2025 Results on March 19, 2026 - Sahm
InflaRx (IFRX) to Release Earnings on Thursday - MarketBeat
Finanzdaten der Inflarx N V-Aktie (IFRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):